First, it is indicated for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, when used alongside a reduced-calorie diet and increased physical activity
CagriSema FDA approval timeline Novo Nordisk submitted the New Drug Application (NDA) to the FDA on December 18, 2025 , for chronic weight management in adults with obesity or overweight with a weight-related comorbidity
For researchers concerned about the muscle wasting associated with GLP-1 medications, this mechanism is highly relevant
Peak plasma concentrations occur within 8 to 72 hours after injection, though the pharmacologic effects are sustained throughout the weekly dosing interval due to the medication's long half-life
Medication Timing Try shifting the timing of your dose around predictable daily patterns, for example, aligning it with a sleep block or a light meal, then observe which slot produces fewer symptoms
Non-Insured Health Benefits (NIHB) Drug Benefit List Indigenous Services Canada Federal program covering prescription drugs for eligible First Nations and Inuit, including Ozempic for type 2 diabetes